The FDA has accepted an sBLA for glofitamab plus gemcitabine and oxaliplatin in relapsed/refractory diffuse large B-cell ...

CRB-701 has gained FDA fast track status for the treatment of adult patients with relapsed/refractory metastatic cervical ...

Patients with multiple myeloma face a complex, decades-long treatment journey involving care coordination, insurance ...

Lung cancer innovations are not only extending lives but also enhancing the quality of life for patients, offering renewed ...